Pollstar Spotlights Venu Holding Corporation Founder J.W. Roth in Exclusive Cover Feature
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Venu Holding Corporation ("VENU" or 'The Company') (NYSE American: VENU), a developer, owner, and operator of upscale live music venues and premium hospitality destinations, revealed today, VENU Founder, Chairman, and CEO J.W. Roth is featured as the cover story of Pollstar's 2025 annual Concert Venue Directory. Pollstar, the leading publication for the global live entertainment industry, recognized for Roth's visionary leadership in developing luxury entertainment campuses across the U.S., Roth shared his vision to redefine the industry and create a truly fan founded, and fan owned future.
Click here to view feature: https://bit.ly/3F1fpxM
Pollstar Magazine has been dubbed 'The Voice of Live Entertainment' for the sports and live entertainment industry for over 40 years, delivering an unmatched archive of live entertainment data and industry news.
About Venu Holding Corporation
Venu Holding Corporation ("VENU") (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to building luxury, experience-driven entertainment destinations. VENU's campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers, and unique to Colorado Springs, Notes Eatery and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU's upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU's vision of redefining the live entertainment experience. Click here for company overview.
VENU has been recognized nationally by The Wall Street Journal, The New York Times, Denver Post, Billboard, VenuesNow, and Variety for its innovative and disruptive approach to live entertainment. Through strategic partnerships with industry leaders such as AEG Presents and NFL Hall of Famer and Founder of EIGHT Elite Light Lager, Troy Aikman, VENU continues to shape the future of the entertainment landscape. For more information, visit venu.live.
Forward Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
51Talk Online Education Group to Present on the Emerging Growth Conference on June 17, 2025.
51Talk Online Education Group invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SINGAPORE, June 12, 2025 /PRNewswire/ -- 51Talk Online Education Group (the "Company") (NYSE American: COE ), a global online education platform with core expertise in English education, is pleased to announce that it has been invited to present on the Emerging Growth Conference on June 17, 2025. The next Emerging Growth Conference is presenting on June 17, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's investor relations vice president David Chung in real time. Mr. David Chung will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to Questions@ or ask your questions during the event and Mr. David Chung will do his best to get through as many of them as possible. 51Talk Online Education Group will be presenting at 9:05 AM Eastern time for 30 minutes. Please register here to ensure you are able to attend the conference and receive any updates that are released. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on and on the Emerging Growth YouTube Channel, We will release a link to that after the event. About the Emerging Growth Conference The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner. The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. All sessions will be conducted through video webcasts and will take place in the Eastern time zone. About 51Talk Online Education Group 51Talk Online Education Group (NYSE American: COE) is a global online education platform with core expertise in English education. The Company's mission is to make quality education accessible and affordable. The Company's online and mobile education platforms enable students to take live interactive English lessons, on demand. The Company connects its students with a large pool of highly qualified teachers that it assembled using a shared economy approach, and employs student and teacher feedback and data analytics to deliver a personalized learning experience to its students. CONTACTS: 51Talk Online Education Group David ChungInvestor Relations Vice Presidentdavidchung@ Jinling WangInvestor Relations Managerwangjinling@ View original content: SOURCE 51Talk Online Education Group Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Indianapolis Star
11 hours ago
- Indianapolis Star
Tecogen to Participate in Roth Conference in London
NORTH BILLERICA, MA / ACCESS Newswire Tecogen Inc. (NYSE American:TGEN) a leading manufacturer of clean energy products, today announced that Abinand Rangesh, Chief Executive Officer, will participate in the 15 th Annual Roth Conference hosted in London, England on June 24 th to 26 th, 2025. Management will be available for one-on-one meetings during the conference. Attending investors interested in meeting Dr. Rangesh should contact their Roth representative or email investorrelations@ About Tecogen Tecogen designs, manufactures, sells, installs, and maintains high efficiency, ultra-clean, cogeneration products including engine-driven combined heat and power, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company provides cost effective, environmentally friendly and reliable products for energy production that nearly eliminate criteria pollutants and significantly reduce a customer's carbon footprint. In business for over 35 years, Tecogen has shipped more than 3,200 units, supported by an established network of engineering, sales, and service personnel in key markets in North America. For more information, please visit or contact us for a free Site Assessment. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and other federal securities laws that involve a number of risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'estimate,' 'project,' 'target,' 'potential,' 'will,' 'should,' 'seek,' 'could,' 'likely,' 'may,' 'pro forma,' 'anticipate,' 'continue,' or other variations thereof (including their use in the negative), or by discussions of strategies, plans or intentions. All statements, other than statements of historical fact included in this press release regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements. In addition to those factors described in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and in our Form 8-K, under 'Risk Factors,' among the factors that could cause actual results to differ materially from past and projected future results are the following: fluctuations in demand for our products and services, competing technological developments, issues relating to research and development, the availability of incentives, rebates, and tax benefits relating to our products and services, changes in the regulatory environment relating to our products and services, integration of acquired business operations, and the ability to obtain financing on favorable terms to fund existing operations and anticipated growth. Tecogen Media & Investor Relations Contact Information: Abinand Rangesh, CEO P: 781-466-6487 E: SOURCE: Tecogen, Inc.
Yahoo
11 hours ago
- Yahoo
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected later this month NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. 'We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month,' said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, 'We have enhanced our financial position with the closing of a $25 million rights offering earlier this month which will support advancing this potential new treatment option for patients suffering from this rare genetic disease.' Rafael Holdings, Inc. Third Quarter Fiscal Year 2025 Financial Results As of April 30, 2025, we had cash and cash equivalents of $37.9 million. On June 4, 2025, the Company announced the closing of a $25 million rights offering, which, including the funding of the backstop commitment by the Jonas family, raised net proceeds of $24.9 million after deduction of certain expenses incurred in connection with the offering. For the three months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $4.8 million, or $0.19 per share, versus a net loss of $32.4 million, or $1.36 per share in the year ago period. The year over year decrease in net loss is attributable to non-cash items, primarily unrealized losses of $1.4 million on the Company's investment in Cyclo equity which we purchased in advance of the potential merger in the current period versus $4.4 million in the year ago period, combined with an in-process R&D expense of $89.9 million related to the acquisition of Cornerstone, partially offset by a $31.3 million recovery of receivables from Cornerstone in the year ago period. Research and development expenses were $3.0 million for the three months ended April 30, 2025, compared to $1.5 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo Therapeutics following the March 25, 2025 merger and the activity of Cornerstone and Day Three which were consolidated with Rafael Holdings during fiscal 2024. General and administrative expenses were $3.2 million for the three months ended April 30, 2025, compared to $1.9 million in the year ago period. The year over year increase relates to the inclusion of Cyclo Therapeutics following closing of the merger, and the activity of Cornerstone and Day Three, following their consolidation. Rafael Holdings, Inc. First Nine Months Fiscal Year 2025 Financial Results For the nine months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $18.4 million, or $0.73 per share, versus a net loss of $29.9 million, or $1.26 per share in the year ago period. The year over year decrease in net loss is attributable to in-process R&D expense of $89.9 million related to the acquisition of Cornerstone net with a $31.3 million recovery of receivables from Cornerstone in the year ago period and $3.2 million in unrealized gains on the Company's investment in Cyclo equity. Research and development expenses were $5.3 million for the nine months ended April 30, 2025, compared to $2.6 million in the year ago period. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024. For the nine months ended April 30, 2025, general and administrative expenses were $8.3 million compared to $6.5 million in the same period in the prior year. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024. About Rafael Holdings, Inc. Rafael Holdings, Inc. holds interests in clinical and early-stage pharmaceutical and certain other companies, including our wholly owned subsidiary, Cyclo Therapeutics, LLC, a clinical stage biotechnology company dedicated to developing Rafael's lead clinical candidate, Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 ('NPC1'), a rare, fatal, and progressive genetic disorder. Rafael also holds majority equity interests in LipoMedix Pharmaceuticals Ltd., a clinical stage pharmaceutical company, Cornerstone Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their existing cannabis offerings. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption 'Risk Factors' in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Contact:Barbara 274-2825 RAFAEL HOLDINGS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) April 30, 2025 July 31, 2024 (audited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 37,936 $ 2,675 Available-for-sale securities — 63,265 Interest receivable — 515 Prepaid clinical trial costs 2,968 — Convertible note receivables, due from Cyclo — 5,191 Accounts receivable, net of allowance for credit losses of $245 at April 30, 2025 and July 31, 2024 414 426 Inventory 288 — Prepaid expenses and other current assets 837 430 Total current assets 42,443 72,502 Property and equipment, net 1,614 2,120 Non-current prepaid clinical trial costs 1,399 — Investments – Cyclo — 12,010 Investments - Hedge Funds — 2,547 Convertible note receivable classified as available-for-sale 1,719 1,146 Goodwill 28,278 3,050 Intangible assets, net 1,027 1,847 In-process research and development 31,575 1,575 Other assets 41 35 TOTAL ASSETS $ 108,096 $ 96,832 LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable $ 7,793 $ 2,556 Accrued expenses 1,866 1,798 Convertible notes payable 614 614 Other current liabilities 93 113 Due to related parties 664 733 Installment note payable — 1,700 Total current liabilities 11,030 7,514 Accrued expenses, noncurrent 3,445 2,982 Convertible notes payable, noncurrent 76 73 Other liabilities 25 5 Deferred income tax liability 9,002 — TOTAL LIABILITIES 23,578 10,574 COMMITMENTS AND CONTINGENCIES EQUITY Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2025 and July 31, 2024 8 8 Class B common stock, $0.01 par value; 200,000,000 shares authorized, 31,240,188 issued and outstanding (excluding treasury shares of 101,487) as of April 30, 2025, and 24,142,535 issued and 23,819,948 outstanding (excluding treasury shares of 101,487) as of July 31, 2024 312 238 Additional paid-in capital 296,648 280,048 Accumulated deficit (220,169 ) (201,743 ) Treasury stock, at cost; 101,487 Class B shares as of October 31, 2024 and July 31, 2024 (168 ) (168 ) Accumulated other comprehensive income related to unrealized income on available-for-sale securities 219 111 Accumulated other comprehensive income related to foreign currency translation adjustment 3,728 3,691 Total equity attributable to Rafael Holdings, Inc. 80,578 82,185 Noncontrolling interests 3,940 4,073 TOTAL EQUITY 84,518 86,258 TOTAL LIABILITIES AND EQUITY $ 108,096 $ 96,832 RAFAEL HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited, in thousands, except share and per share data) Three Months Ended April 30, Nine Months Ended April 30, 2025 2024 2025 2024 Revenues $ 362 $ 336 $ 567 $ 472 Cost of Infusion Technology revenue 31 85 106 85 Cost of product revenue 9 — 9 — SG&A Expenses 3,170 1,923 8,284 6,524 R&D Expenses 3,003 1,526 5,276 2,627 In-process R&D expense — 89,861 — 89,861 Depreciation and amortization 62 102 238 157 Loss on impairment of goodwill — — 3,050 — Operating Loss (5,913 ) (93,161 ) (16,396 ) (98,782 ) Interest income 472 502 1,529 1,777 Loss on initial investment in Day Three upon acquisition — — — (1,633 ) Realized gain on available-for-sale securities — 945 178 1,521 Realized loss on investment in equity securities — — — (46 ) Realized gain on investment - Cyclo — — — 424 Unrealized (loss) gain on investments - Cyclo (1,393 ) (4,395 ) (5,144 ) 3,199 Unrealized gain (loss) on convertible notes receivable, due from Cyclo 383 — (719 ) — Unrealized loss on investments - Hedge Funds — (3 ) — (118 ) Recovery of receivables from Cornerstone — 31,305 — 31,305 Interest expense (165 ) (85 ) (490 ) (85 ) Other income, net 154 — 74 118 Loss before Incomes Taxes (6,462 ) (64,892 ) (20,968 ) (62,320 ) Benefit from income taxes 2,411 2,599 2,379 2,593 Equity in loss of Day Three — — — (422 ) Consolidated net loss (4,051 ) (62,293 ) (18,589 ) (60,149 ) Net income (loss) attributable to noncontrolling interests 728 (29,942 ) (163 ) (30,207 ) Net loss attributable to Rafael Holdings, Inc. $ (4,779 ) $ (32,351 ) $ (18,426 ) $ (29,942 ) Loss per share Basic and diluted (0.19 ) (1.36 ) (0.73 ) (1.26 ) Loss per basic common share $ (0.19 ) $ (1.36 ) $ (0.73 ) $ (1.26 ) Weighted average shares in calculation 25,238,501 23,777,493 23,131,655 23,687,781 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
